Since LPS but not OA, is known to activate NF-κB30,31, part of the beneficial effects of methylprednisolone in our OA-LPS ARDS model might be explained by the inhibition of the NF-κB signalling pathway through the GCR. Here, NR3C1 is linked to acute respiratory distress syndrome.